ZLD — Zelira Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$3.97m
- AU$10.66m
- AU$0.10m
Annual income statement for Zelira Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.04 | 2.09 | 2.89 | 0.551 | 0.095 |
| Cost of Revenue | |||||
| Gross Profit | — | 1.86 | 1.95 | 0.189 | 0.011 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 7.94 | 10.6 | 15.3 | 6.82 | 36.8 |
| Operating Profit | -6.9 | -8.51 | -12.4 | -6.27 | -36.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -7.02 | -8.55 | -12.4 | -6.27 | -36.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.02 | -8.55 | -12.4 | -6.27 | -36.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.02 | -8.55 | -11.9 | -5.57 | -36.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.02 | -8.55 | -11.9 | -5.57 | -36.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.39 | -1.21 | -1.41 | -0.527 | -0.492 |